. Author manuscript; available in PMC: 2024 Sep 25.

Published in final edited form as: Cancer. 2023 Nov 29;130(7):1052–1060. doi: 10.1002/cncr.35136

Table 3.

Number needed to treat with cALND to determine abemaciclib candidacy among females with HR+HER2- non-metastatic invasive breast cancer and 1–3 positive sentinel lymph nodes without high-risk features who underwent upfront surgery and completion axillary lymph node dissection.

		Total number of positive LNs after cALND [n (row %)]			Number Needed to Treat [n (95% CI)]
		Overall	1–3	≥4	Number Needed to Treat [n (95% CI)]
Number of positive SLNs	Overall	1,762	1,456 (82.6)	306 (17.4)
	1	1,159	1,048 (90.4)	111 (9.6)	11 (9, 13)
	2	419	317 (75.7)	102 (24.3)	5 (4, 5)
	3	184	91 (49.5)	93 (50.5)	2 (2, 3)

Abbreviations: cALND: completion axillary lymph node dissection; CI: confidence interval; SLN: sentinel lymph node; LN: total lymph nodes